FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2806443421> ?p ?o ?g. }

• W2806443421 endingPage "886" @default.
• W2806443421 startingPage "878" @default.
• W2806443421 abstract "Background & AimsFunctional nausea and vomiting disorders (FNVDs) are classified as chronic nausea and vomiting syndrome (CNVS) or cyclic vomiting syndrome (CVS)—CVS includes cannabinoid hyperemesis syndrome. We investigated the population prevalence of FNVDs, their characteristics, and associated factors.MethodsIn the year 2015, an Internet cross-sectional health survey was completed by 5931 adults in the general populations of 3 English-speaking countries; 2100 participants were in the United States, Canada, or the United Kingdom. Quota-based sampling was used to generate demographically balanced and population-representative samples. The survey collected data on demographics, health care visits, medications, somatic symptom severity, quality of life, and symptom-based diagnostic criteria for Rome IV FNVDs as well as for irritable bowel syndrome and functional dyspepsia. Subsequent comparisons were made between Rome IV FNVD subjects and individuals without FNVDs (controls).ResultsOverall, 2.2% of the population (n = 131) fulfilled symptom-based diagnostic criteria for Rome IV FNVDs: the United States (3%) had a greater prevalence than Canada (1.9%) or the United Kingdom (1.8%) (P = .02). The prevalence of CNVS was similar among the countries, ranging from 0.8% to 1.2%. However, the prevalence of CVS was higher in the United States (2%) than in Canada (0.7%) or the United Kingdom (1%) (P = .03). The proportion of subjects with CVS taking cannabis did not differ significantly among countries (P = .31), although the 7 cases of cannabinoid hyperemesis syndrome were in the United States. A significantly higher proportion of subjects with CVS reported a compulsive need for hot water bathing to alleviate emetic symptoms than subjects with CNVS (44% vs 19%; P = .03); this behavior was independent of cannabis but augmented by its use. Subjects with FNVDs had significantly greater health impairment and health care utilization than controls. On multivariate analysis, independent factors associated with FNVDs were younger age, increasing somatic symptom severity, lower quality of life, presence of irritable bowel syndrome, and functional dyspepsia. However, on subgroup analysis, somatic symptom severity was associated with CVS but not CNVS, whereas poor quality of life was associated with CNVS but not CVS.ConclusionsBased on a cross-sectional health survey of adults in the general populations of 3 English-speaking countries, approximately 2% of subjects meet symptom-based criteria for Rome IV FNVDs and have considerable health impairments. Hot water bathing to alleviate emetic symptoms is reported for all FNVDs, and is perpetuated by cannabis use. Functional nausea and vomiting disorders (FNVDs) are classified as chronic nausea and vomiting syndrome (CNVS) or cyclic vomiting syndrome (CVS)—CVS includes cannabinoid hyperemesis syndrome. We investigated the population prevalence of FNVDs, their characteristics, and associated factors. In the year 2015, an Internet cross-sectional health survey was completed by 5931 adults in the general populations of 3 English-speaking countries; 2100 participants were in the United States, Canada, or the United Kingdom. Quota-based sampling was used to generate demographically balanced and population-representative samples. The survey collected data on demographics, health care visits, medications, somatic symptom severity, quality of life, and symptom-based diagnostic criteria for Rome IV FNVDs as well as for irritable bowel syndrome and functional dyspepsia. Subsequent comparisons were made between Rome IV FNVD subjects and individuals without FNVDs (controls). Overall, 2.2% of the population (n = 131) fulfilled symptom-based diagnostic criteria for Rome IV FNVDs: the United States (3%) had a greater prevalence than Canada (1.9%) or the United Kingdom (1.8%) (P = .02). The prevalence of CNVS was similar among the countries, ranging from 0.8% to 1.2%. However, the prevalence of CVS was higher in the United States (2%) than in Canada (0.7%) or the United Kingdom (1%) (P = .03). The proportion of subjects with CVS taking cannabis did not differ significantly among countries (P = .31), although the 7 cases of cannabinoid hyperemesis syndrome were in the United States. A significantly higher proportion of subjects with CVS reported a compulsive need for hot water bathing to alleviate emetic symptoms than subjects with CNVS (44% vs 19%; P = .03); this behavior was independent of cannabis but augmented by its use. Subjects with FNVDs had significantly greater health impairment and health care utilization than controls. On multivariate analysis, independent factors associated with FNVDs were younger age, increasing somatic symptom severity, lower quality of life, presence of irritable bowel syndrome, and functional dyspepsia. However, on subgroup analysis, somatic symptom severity was associated with CVS but not CNVS, whereas poor quality of life was associated with CNVS but not CVS. Based on a cross-sectional health survey of adults in the general populations of 3 English-speaking countries, approximately 2% of subjects meet symptom-based criteria for Rome IV FNVDs and have considerable health impairments. Hot water bathing to alleviate emetic symptoms is reported for all FNVDs, and is perpetuated by cannabis use." @default.
• W2806443421 created "2018-06-13" @default.
• W2806443421 creator A5014766330 @default.
• W2806443421 creator A5026610665 @default.
• W2806443421 creator A5058926785 @default.
• W2806443421 creator A5065772328 @default.
• W2806443421 creator A5067820597 @default.
• W2806443421 creator A5087162630 @default.
• W2806443421 date "2019-04-01" @default.
• W2806443421 modified "2023-10-18" @default.
• W2806443421 title "Epidemiology, Clinical Characteristics, and Associations for Rome IV Functional Nausea and Vomiting Disorders in Adults" @default.
• W2806443421 cites W1485718575 @default.
• W2806443421 cites W1535269983 @default.
• W2806443421 cites W1551200140 @default.
• W2806443421 cites W1589230213 @default.
• W2806443421 cites W1966979343 @default.
• W2806443421 cites W1970409352 @default.
• W2806443421 cites W1999640073 @default.
• W2806443421 cites W2074751996 @default.
• W2806443421 cites W2081041886 @default.
• W2806443421 cites W2099964125 @default.
• W2806443421 cites W2124961627 @default.
• W2806443421 cites W2132945739 @default.
• W2806443421 cites W2253496291 @default.
• W2806443421 cites W2336162664 @default.
• W2806443421 cites W2341266334 @default.
• W2806443421 cites W2342528407 @default.
• W2806443421 cites W2344547018 @default.
• W2806443421 cites W2345655271 @default.
• W2806443421 cites W2558019940 @default.
• W2806443421 cites W2561559498 @default.
• W2806443421 cites W2597634683 @default.
• W2806443421 cites W2726535468 @default.
• W2806443421 cites W2734633105 @default.
• W2806443421 cites W2739045117 @default.
• W2806443421 cites W2768060498 @default.
• W2806443421 cites W2768229082 @default.
• W2806443421 cites W2770539178 @default.
• W2806443421 cites W4211073917 @default.
• W2806443421 cites W4249534836 @default.
• W2806443421 cites W4255279872 @default.
• W2806443421 doi "https://doi.org/10.1016/j.cgh.2018.05.020" @default.
• W2806443421 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29857155" @default.
• W2806443421 hasPublicationYear "2019" @default.
• W2806443421 type Work @default.
• W2806443421 sameAs 2806443421 @default.
• W2806443421 citedByCount "82" @default.
• W2806443421 countsByYear W28064434212018 @default.
• W2806443421 countsByYear W28064434212019 @default.
• W2806443421 countsByYear W28064434212020 @default.
• W2806443421 countsByYear W28064434212021 @default.
• W2806443421 countsByYear W28064434212022 @default.
• W2806443421 countsByYear W28064434212023 @default.
• W2806443421 crossrefType "journal-article" @default.
• W2806443421 hasAuthorship W2806443421A5014766330 @default.
• W2806443421 hasAuthorship W2806443421A5026610665 @default.
• W2806443421 hasAuthorship W2806443421A5058926785 @default.
• W2806443421 hasAuthorship W2806443421A5065772328 @default.
• W2806443421 hasAuthorship W2806443421A5067820597 @default.
• W2806443421 hasAuthorship W2806443421A5087162630 @default.
• W2806443421 hasBestOaLocation W28064434212 @default.
• W2806443421 hasConcept C107130276 @default.
• W2806443421 hasConcept C118552586 @default.
• W2806443421 hasConcept C126322002 @default.
• W2806443421 hasConcept C187212893 @default.
• W2806443421 hasConcept C2776490719 @default.
• W2806443421 hasConcept C2777056318 @default.
• W2806443421 hasConcept C2780580376 @default.
• W2806443421 hasConcept C2780852908 @default.
• W2806443421 hasConcept C2908647359 @default.
• W2806443421 hasConcept C71924100 @default.
• W2806443421 hasConcept C99454951 @default.
• W2806443421 hasConceptScore W2806443421C107130276 @default.
• W2806443421 hasConceptScore W2806443421C118552586 @default.
• W2806443421 hasConceptScore W2806443421C126322002 @default.
• W2806443421 hasConceptScore W2806443421C187212893 @default.
• W2806443421 hasConceptScore W2806443421C2776490719 @default.
• W2806443421 hasConceptScore W2806443421C2777056318 @default.
• W2806443421 hasConceptScore W2806443421C2780580376 @default.
• W2806443421 hasConceptScore W2806443421C2780852908 @default.
• W2806443421 hasConceptScore W2806443421C2908647359 @default.
• W2806443421 hasConceptScore W2806443421C71924100 @default.
• W2806443421 hasConceptScore W2806443421C99454951 @default.
• W2806443421 hasFunder F4320312155 @default.
• W2806443421 hasFunder F4320322992 @default.
• W2806443421 hasFunder F4320323764 @default.
• W2806443421 hasFunder F4320337357 @default.
• W2806443421 hasIssue "5" @default.
• W2806443421 hasLocation W28064434211 @default.
• W2806443421 hasLocation W28064434212 @default.
• W2806443421 hasLocation W28064434213 @default.
• W2806443421 hasOpenAccess W2806443421 @default.
• W2806443421 hasPrimaryLocation W28064434211 @default.
• W2806443421 hasRelatedWork W1554373293 @default.
• W2806443421 hasRelatedWork W1745760373 @default.
• W2806443421 hasRelatedWork W2011695029 @default.
• W2806443421 hasRelatedWork W2019532713 @default.
• W2806443421 hasRelatedWork W2101260348 @default.

• next